Some of the roughly 1 million cases a year of the parasitic disease leishmaniasis don't fit with the standard definition of the disease--the patients have unusual symptoms and front-line medicines don't work. Now, researchers have discovered why many of these cases are so different--they're caused by parasites with distinct genetic variations. The finding, reported in PLOS Neglected Tropical Diseases, was made by studying patients in northeast Brazil but may hold true elsewhere around the world.
Leishmania impression smear. Courtesy of Michael Wunderli, Flickr
Some of the roughly 1 million cases a year of the parasitic disease leishmaniasis don't fit with the standard definition of the disease--the patients have unusual symptoms and front-line medicines don't work. Now, researchers have discovered why many of these cases are so different--they're caused by parasites with distinct genetic variations. The finding, reported in PLOS Neglected Tropical Diseases, was made by studying patients in northeast Brazil but may hold true elsewhere around the world.
Leishmaniasis is a parasitic disease caused by infection with Leishmania parasites, which are spread by sand flies in the tropics, subtropics, and southern Europe. Bites from flies carrying the parasite may turn into skin lesions which can become infected with bacteria. Brazil is one of six countries where 90 percent of new cases occur. However, a small percentage of these cases don't fit into the most commonly recognized subtypes of the cutaneous disease. Previously, researchers have attributed these atypical cases (ACL) to the patients themselves, who may have chronic diseases or be pregnant. However, many patients don't fit this pattern, suggesting there are other factors at play. Between 2005 and 2012, Luiz Henrique Guimarães, Albert Schriefer, of the Universidade Federal da Bahia in Brazil, and colleagues, followed 51 patients with ACL and 51 matched cutaneous leishmaniasis (CL) patients. The researchers collected not only clinical data, but blood and skin samples to study both the genetics of the parasite infecting each patient, as well as their body's immune response to the disease.
The team found that patients with ACL had significantly more lesions, particularly above the waist, than those with standard CL. Moreover, their disease typically lasted longer and was more likely to be resistant to antimony, the front-line treatment used in Brazil. While 98% of CL patients healed after one or two courses of the drug, only 35% of ACL patients were treated after two courses. The researchers went on to show that the ACL found in the northeast of Brazil is caused by a genetically distinct strain of Leishmania braziliensis; the parasites from 62.5% of ACL patients studied had genetic variations seen only in ACL. Finally, levels of inflammatory cytokines, produced by the immune system, were higher in ACL.
"Precise identification of ACL is important because it usually does not readily respond to drugs commonly used to treat leishmaniasis in Brazil, but readily responds to other treatment options available," the researchers write. "These findings may contribute to our understanding of the pathogenesis of ACL, and ultimately to a more logical approach to management of this and other unusual forms of [leishmaniasis]."
Reference: Guimarães LH, Queiroz A, Silva JA, Silva SC, Magalhães V, Lago EL, et al. (2016) Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for Leishmania braziliensis: Clinical, Immunological and Parasitological Aspects. PLoS Negl Trop Dis 10(12): e0005100. doi:10.1371/journal.pntd.0005100
Source: PLOS
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
Announcing the 2024 Infection Control Today Educator of the Year: Shahbaz Salehi, MD, MPH, MSHIA
December 17th 2024Shahbaz Salehi, MD, MPH, MSHIA, is the Infection Control Today 2024 Educator of the Year. He is celebrated for his leadership, mentorship, and transformative contributions to infection prevention education and patient safety.
Pula General Hospital Celebrates Clean Hospitals
December 16th 2024Learn how Pula General Hospital in Croatia championed infection prevention and environmental hygiene and celebrated Clean Hospitals Day to honor cleaning staff and promote advanced practices for exceptional patient care and safety.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.